Globus Medical (GMED) Cash & Equivalents (2011 - 2026)

Globus Medical (GMED) has reported Cash & Equivalents for 16 consecutive years, with $507.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 121.29% year-over-year to $507.7 million; the trailing twelve-month figure through Jun 2026 stood at $507.7 million (up 121.29% YoY), and the FY2025 full-year result was $526.2 million, down 32.93% from the prior year.
• Cash & Equivalents declined to $507.7 million in Q2 2026 per GMED's latest filing, from $560.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $784.4 million in Q4 2024 and bottomed at $134.2 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $375.9 million across 5 years, with a median of $362.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 62.91% in 2022, then surged 210.56% in 2023.
• Over 5 years, Cash & Equivalents stood at $150.5 million in 2022, then soared by 210.56% to $467.3 million in 2023, then surged by 67.87% to $784.4 million in 2024, then slumped by 32.93% to $526.2 million in 2025, then slipped by 3.5% to $507.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $507.7 million, $560.9 million, and $526.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.